ADC Therapeutics (ADCT)
Develops and sells ZYNLONTA while pursuing broader lymphoma use.
Something off on this page? Send us feedback.
Sells ZYNLONTA in the U.S. for later-line large B-cell lymphoma and earns ex-U.S. license and royalty economics through partners. A single reportable segment concentrates the business on targeted ADC cancer therapies and ZYNLONTA expansion trials.
Commercial activity centers on ZYNLONTA, a CD19-directed antibody drug conjugate approved for relapsed or refractory large B-cell lymphoma after prior systemic therapy. Product revenue comes from direct U.S. sales, while partners support Japan, China-linked territories, and other ex-U.S. markets through license and royalty economics.
Clinical work is concentrated on ZYNLONTA expansion: LOTIS-5 for a confirmatory rituximab combination, LOTIS-7 with glofitamab, and investigator-initiated studies in indolent lymphomas. ADCT-241, a PSMA-targeting ADC, remains a partnering focus after IND-enabling work.
Operations are being reshaped around regulatory, medical-affairs, and commercial execution for ZYNLONTA. Continued approval and broader use depend on confirmatory evidence, benefit-risk review, partner execution outside the U.S., royalty obligations, and a leaner post-restructuring cost base.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jun 8, 2026 | HC Wainwright & Co. | Downgrade | Buy | Neutral | ||
| Jun 4, 2026 | Stephens | Target | $5 | |||
| Jun 4, 2026 | RBC Capital | Downgrade | Outperform | Sector Perform | ||
| Jun 3, 2026 | RBC Capital | Target | $5 | $2 | ||
| Dec 3, 2025 | RBC Capital | Target | $5 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $219.1M · Total debt $417.1M · Total assets $279.4M · Shareholders' equity −$228.2M
- Revenue
- $19.2M
- Operating income
- −$25.4M
- Net income
- −$16.6M
No dividends on record.
| Institutions122 holders · as of Mar 31, 2026 · largest filers plus last quarter's tail | ≈ 65.40% | 83.50M shares | |
| Insiders14 holders · as of Jul 2, 2026 | 12.28% | 15.68M shares | |
| Strategic holders2 holders · as of Feb 17, 2026 | 15.71% | 20.06M shares | |
| Otherremainder | ≈ 6.61% | 8.43M shares |
127.67M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Redmile Group, LLCInstitution | 12.12% | 15.47M | 13Fas of Mar 31, 2026 |
TCG Crossover Management, LLCInstitution | 8.92% | 11.39M | 13Fas of Mar 31, 2026 |
TCG Crossover GP II, LLCStrategic | 8.92% | 11.39M | 13Gfiled Feb 17, 2026 ↗ |
Hans Peter WildInsider10 percent owner | 7.67% | 9.79M | Form 4filed May 19, 2025 ↗ |
HPWH TH AGStrategic | 6.79% | 8.67M | 13Gfiled May 19, 2025 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 2, 2026 | Redmile Group, LLC | 10 percent owner | −5,163,997 | $3.28 |
| Apr 1, 2026 | Redmile Group, LLC | 10 percent owner | −331,782 | $3.80 |
| Mar 31, 2026 | Redmile Group, LLC | 10 percent owner | −384,636 | $3.75 |
| Oct 27, 2025 | Redmile Group, LLC | 10 percent owner | +3,846,153 |
- Gilead Sciences
CD19 CAR-T alternative in relapsed or refractory LBCL
- Bristol-Myers Squibb
CAR-T alternative across second-line and later LBCL
- Genmab (ADR)
CD20xCD3 bispecific overlap in 3L+ DLBCL
- AbbVie
Co-commercial bispecific overlap in R/R DLBCL
- Novartis (ADR)
CD19 CAR-T option after two prior lymphoma treatments
- Incyte
CD19 antibody regimen in transplant-ineligible R/R DLBCL
- Pfizer
ADC oncology platform with lymphoma-directed Adcetris
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| ADC Therapeutics | $1.31 | −1.13% | $167.9M | — | — | 2.1 | +2.2% |
| Gilead Sciences | $149.20 | −0.27% | $185.75B | — | 16.5 | 6.1 | +10.2% |
| Bristol-Myers Squibb | $67.64 | −0.02% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Genmab (ADR) | $34.37 | +0.45% | $21.01B | 27.0 | 26.6 | 2.1 | +24.9% |
| AbbVie | $261.07 | −0.24% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Novartis (ADR) | $161.87 | −0.35% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Incyte | $128.82 | +3.05% | $26.11B | 16.4 | 53.4 | 4.5 | +37.7% |
| Pfizer | $28.99 | −0.14% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Median | 25.7 | 17.2 | 4.5 | +10.2% |